Research analysts covering Clearmind Medicine.
Recent press releases and 8-K filings for CMND.
Clearmind Medicine's MEAI Included in U.S. Congress' Emerging Therapies Bill
CMND
New Projects/Investments
- Clearmind Medicine Inc.'s proprietary compound, MEAI (5-methoxy-2-aminoindane, or 5-MeO-AI), has been included in newly introduced bipartisan legislation in the U.S. Congress.
- The legislation, titled , directs the Department of Veterans Affairs (VA) to establish an investigational research and extended access treatment program for innovative therapies addressing unmet medical needs in veterans.
- This marks the first time MEAI, described as a next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation.
- If passed, H.R. 7091 could transform clinical treatment for various conditions, including Alcohol Use Disorder and post-traumatic stress disorder, by developing VA-supported clinical trials and extended access protocols.
4 days ago
Clearmind Medicine Inc. Reports Key 2025 Clinical Trial Progress and IP Expansion
CMND
New Projects/Investments
- Clearmind Medicine Inc. advanced its FDA-approved Phase I/IIa clinical trial for CMND-100 for Alcohol Use Disorder (AUD) in 2025, initiating first-in-human dosing and completing enrollment and treatment for the first two cohorts.
- The trial reported positive top-line safety and tolerability results with no serious adverse events.
- The Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial, reinforcing CMND-100's safety profile.
- The company also strengthened its intellectual property portfolio with multiple international patent filings for non-hallucinogenic neuroplastogen patents targeting various indications such as weight loss, obesity, and mental health disorders.
Dec 29, 2025, 11:03 AM
Clearmind Medicine Regains Nasdaq Minimum Stockholders' Equity Compliance
CMND
Delisting/Listing Issues
- Clearmind Medicine Inc. successfully regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates listed companies maintain stockholders' equity of at least $2,500,000.
- The company received notification from Nasdaq on December 10, 2025, confirming its compliance.
- Nasdaq will continue to monitor Clearmind Medicine's adherence to the Minimum Stockholders' Equity Rule, and failure to demonstrate compliance in the next periodic report could result in delisting.
Dec 12, 2025, 11:35 AM
Clearmind Medicine Advances CMND-100 to Dosing Phase in AUD Clinical Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. announced a key milestone in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD).
- The first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel.
- This advancement follows positive top-line results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board to continue the trial.
Dec 2, 2025, 1:32 PM
Clearmind Medicine Inc. Announces Registered Direct Offering
CMND
Equity Offering
New Projects/Investments
- Clearmind Medicine Inc. entered into a definitive securities purchase agreement on November 26, 2025, for a registered direct offering with investors.
- The offering includes the sale of 7,944,868 common shares at $0.12 per share and pre-funded warrants to purchase up to 2,865,960 common shares at $0.1199 per pre-funded warrant.
- The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share and will not expire until exercised in full, subject to a 4.99% beneficial ownership limitation.
- The company expects to receive approximately $1.294 million in aggregate gross proceeds from the offering, which will be used for general corporate purposes, including operating expenses, research and development, working capital, and potential acquisitions.
Nov 26, 2025, 1:48 PM
Clearmind Medicine Initiates Patient Enrollment at Tel Aviv Sourasky Medical Center for CMND-100 AUD Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. has commenced patient enrollment at the Tel Aviv Sourasky Medical Center (TASMC) for its FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder (AUD).
- The activation of TASMC as a trial site, under Principal Investigator Prof. David Zeltser, expands the network of participating centers, which also includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.
- The Phase I/IIa trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, which is Clearmind's proprietary, non-hallucinogenic, oral MEAI-based compound.
- Recent top-line results from the first completed cohort of the trial showed excellent safety and adherence with no serious adverse events.
Nov 25, 2025, 9:01 PM
Clearmind Medicine Activates Fifth Clinical Trial Site for CMND-100
CMND
New Projects/Investments
- Clearmind Medicine Inc. has activated Hadassah Medical Center in Jerusalem, Israel, as the fifth global medical site for its FDA-approved Phase I/IIa clinical trial for CMND-100.
- CMND-100 is a proprietary non-hallucinogenic MEAI-based oral drug candidate developed to address Alcohol Use Disorder (AUD).
- The multinational, multi-center study evaluates the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption.
- Top-line data from the first cohort of the clinical trial showed a favorable safety profile with no serious adverse events reported, and the treatment was generally well-tolerated across all participants.
Nov 20, 2025, 1:08 PM
Clearmind Medicine Inc. Announces $2.185 Million Registered Direct Offering
CMND
New Projects/Investments
M&A
- Clearmind Medicine Inc. entered into a securities purchase agreement on November 19, 2025, for a registered direct offering of 10,925,000 common shares at a purchase price of $0.20 per Common Share.
- The offering is expected to close on or about November 20, 2025, with anticipated aggregate gross proceeds to the company of approximately $2.185 million.
- The net proceeds from the offering will be used for general corporate purposes, which may include operating expenses, research and development (including clinical and pre-clinical testing of product candidates), working capital, future acquisitions, and general capital expenditures.
Nov 19, 2025, 11:09 AM
Clearmind Medicine Announces Positive Top-Line Results from Phase I/IIa Clinical Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD).
- The first cohort demonstrated a favorable safety profile, with no serious adverse events reported, and the treatment was generally well-tolerated by all participants.
- The trial also showed strong treatment observance and high adherence to the dosing regimen and protocol requirements.
- These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD.
Nov 18, 2025, 9:16 PM
Clearmind Medicine Inc. Announces Registered Direct Offering
CMND
- Clearmind Medicine Inc. entered into a Securities Purchase Agreement on November 17, 2025, for a registered direct offering of common shares and pre-funded warrants.
- The offering includes 3,991,768 common shares at $0.25 per share and pre-funded warrants to purchase 1,518,000 common shares at $0.2499 per warrant.
- The pre-funded warrants are immediately exercisable at $0.0001 per common share and do not expire until exercised in full.
- The offering is expected to generate approximately $1.377 million in aggregate gross proceeds and is anticipated to close on or about November 18, 2025.
- Net proceeds from the offering will be used for general corporate purposes, including operating expenses, research and development, working capital, and future acquisitions.
Nov 17, 2025, 11:15 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more